SCHEMBL19720786

SCHEMBL19720786

CC(C)(C)OC(=O)N1CCCC[C@@H](N(N)c2c(N)ccc(OCCN3CCCC3)c2Cl)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRK1 P41145 1/20 0.39
▸ BACE1 P56817 2/20 0.37
▸ CTSD P07339 1/20 0.37
▸ PDE4B Q07343 1/20 0.36
▸ BCHE P06276 2/20 0.36
▸ HTR6 P50406 2/20 0.36
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ CACNA1F O60840 2/20 0.36
▸ CACNA1D Q01668 2/20 0.36
▸ CACNA1S Q13698 2/20 0.36
▸ CACNA1C Q13936 2/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ PRMT5 O14744 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ ESR1 P03372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19720790 0.89 ALDH1A1 (0.42) OPRK1BCHEHTR6KDM4EGAA
SCHEMBL19720631 0.86 PDE4B (0.46) BACE1CTSDPDE4BUSP30HDAC1
SCHEMBL16895590 0.83 USP30 (0.39) BACE1CTSDBCHEHTR6USP30
SCHEMBL16895591 0.83 USP30 (0.39) BACE1CTSDBCHEHTR6USP30
SCHEMBL16895734 0.76 BTK (0.39) OPRK1BACE1CTSDPDE4BBCHE
SCHEMBL16895737 0.76 BTK (0.39) OPRK1BACE1CTSDPDE4BBCHE
SCHEMBL19720586 0.76 USP30 (0.43) BACE1CTSDUSP30HDAC1HDAC2
SCHEMBL19720629 0.75 PDE4B (0.42) PDE4BUSP30
SCHEMBL16895672 0.75 HCAR1 (0.45) OPRK1PDE4BBCHEHTR6
SCHEMBL16895670 0.75 HCAR1 (0.45) OPRK1PDE4BBCHEHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3257848-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY Novartis AG (CH) 2017-12-20 — — EP disclosed
Send feedback